However, the increased risk of urinary and genital tract infections observed in patients treated with SGLT2i, the possible occurrence of volume depletion, and the development of diabetic ketoacidosis among patients with type 2 diabetes make the use of SGLT2 inhibitors less attractive in acutely ill hospitalized patients with hyperglycemia [3]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.